Back to Search
Start Over
Sustained intraocular pressure elevation after intravitreal injection of bevacizumab and ranibizumab associated with trabeculitis
- Source :
- The Open Ophthalmology Journal
- Publication Year :
- 2010
-
Abstract
- Anti-vascular endothelial growth factor agents are frequently used to treat a variety of ocular neovascular diseases. While agents like bevacizumab and ranibizumab appear to be safe and effective, there have been reports of severe intraocular inflammation as well as sustained elevation of intraocular pressure (IOP) after single or multiple intravitreal injections of these protein-based therapeutics. The true mechanism leading to inflammation and/or sustained spikes in IOP remains unknown. We report a patient with sustained IOP elevation and kerato-precipitates on the trabecular meshwork after multiple injections of both bevacizumab and ranibizumab. We propose that monomer antibodies, aggregated proteins, or other high molecular weight molecules might lead to inflammation in the trabecular meshwork and subsequent elevation in IOP.
- Subjects :
- Intraocular pressure
medicine.medical_specialty
Bevacizumab
genetic structures
medicine.medical_treatment
Glaucoma
Inflammation
neovascular age-related macular degeneration
Article
chemistry.chemical_compound
Ophthalmology
medicine
ranibizumab
vascular endothelial growth factor
business.industry
Growth factor
trabeculitis
medicine.disease
eye diseases
Vascular endothelial growth factor
medicine.anatomical_structure
glaucoma
chemistry
Trabecular meshwork
sense organs
Ranibizumab
medicine.symptom
business
inflammation
medicine.drug
intraocular pressure
Subjects
Details
- ISSN :
- 18743641
- Volume :
- 4
- Database :
- OpenAIRE
- Journal :
- The open ophthalmology journal
- Accession number :
- edsair.doi.dedup.....a6b24d2a69f9cb838c33de8a0054c8da